Moberg Pharma AB (publ) (STO:MOB)
Sweden · Delayed Price · Currency is SEK 11.08
+0.14 (1.28%)
Aug 14, 2026, 5:29 PM CET
Moberg Pharma AB Income Statement
Financials in millions SEK. Fiscal year is January - December.
Millions SEK. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 16.76 | 13.54 | 9.81 | - | 0.21 | - | |
Revenue Growth | 35.76% | 37.99% | - | - | -99.39% | - |
Cost of Revenue | 6.32 | 5.86 | 3.5 | - | - | - |
Gross Profit | 10.44 | 7.68 | 6.32 | - | 0.21 | - |
Selling, General & Admin | 30.16 | 32.14 | 28.97 | 24.86 | 21.07 | 18.51 |
Research & Development | 5.47 | 3.54 | 302.23 | 3.66 | 1.18 | 3.45 |
Other Operating Expenses | -4.47 | - | - | -0.61 | -1.52 | -2.23 |
Operating Expenses | 31.16 | 35.68 | 331.2 | 27.91 | 20.72 | 19.73 |
Operating Income | -20.72 | -28 | -324.89 | -27.91 | -20.52 | -19.73 |
Interest Expense | -0.14 | -0.18 | -0.23 | -0.26 | -0.07 | -0.13 |
Interest & Investment Income | 2.98 | 3.48 | 4.58 | 2.3 | 0.79 | - |
Currency Exchange Gain (Loss) | 0.68 | 0.68 | 0.06 | 0.45 | 0.29 | - |
Other Non Operating Income (Expenses) | - | - | - | - | - | -0.11 |
EBT Excluding Unusual Items | -17.19 | -24.02 | -320.47 | -25.42 | -19.51 | -19.97 |
Pretax Income | -17.19 | -24.02 | -320.47 | -25.42 | -19.51 | -19.97 |
Income Tax Expense | 4.42 | 3.22 | -65.36 | -4.33 | -3.8 | -3.75 |
Earnings From Continuing Operations | -21.62 | -27.24 | -255.11 | -21.09 | -15.71 | -16.22 |
Earnings From Discontinued Operations | - | - | - | - | - | 23.59 |
Net Income to Company | -21.62 | -27.24 | -255.11 | -21.09 | -15.71 | 7.37 |
Minority Interest in Earnings | - | - | - | - | - | 0.13 |
Net Income | -21.62 | -27.24 | -255.11 | -21.09 | -15.71 | 7.49 |
Net Income to Common | -21.62 | -27.24 | -255.11 | -21.09 | -15.71 | 7.49 |
Net Income Growth | - | - | - | - | - | 27.73% |
Shares Outstanding (Basic) | 46 | 47 | 38 | 16 | 8 | 4 |
Shares Outstanding (Diluted) | 46 | 47 | 38 | 16 | 8 | 4 |
Shares Change | 0.04% | 23.78% | 138.46% | 109.19% | 76.28% | 127.45% |
EPS (Basic) | -0.47 | -0.58 | -6.74 | -1.33 | -2.07 | 1.74 |
EPS (Diluted) | -0.47 | -0.58 | -6.74 | -1.33 | -2.07 | 1.70 |
EPS Growth | - | - | - | - | - | -44.56% |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | -13.45 | -17.49 | -16.47 | -33.21 | -16.84 | -15.3 |
Free Cash Flow Per Share | -0.29 | -0.37 | -0.43 | -2.09 | -2.22 | -3.55 |
Gross Margin | 62.31% | 56.73% | 64.37% | - | 100.00% | - |
Operating Margin | -123.61% | -206.80% | -3311.46% | - | -9911.59% | - |
Profit Margin | -128.96% | -201.18% | -2600.26% | - | -7589.37% | - |
Free Cash Flow Margin | -80.23% | -129.18% | -167.87% | - | -8136.23% | - |
EBITDA | -20.02 | -27.3 | -324.89 | -26.96 | -19.62 | -19.73 |
EBITDA Margin | -119.42% | -201.63% | - | - | - | - |
D&A For EBITDA | 0.7 | 0.7 | 0 | 0.95 | 0.9 | 0 |
EBIT | -20.72 | -28 | -324.89 | -27.91 | -20.52 | -19.73 |
EBIT Margin | -123.61% | -206.80% | - | - | - | - |